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INTRODUCTION 
Intake of PRs, in enough quantity and for stated period, 
improves health, well-being, and wealth of the consumer 
1, 
2
. Nowadays, their products pushed up for curing illness, 
and improving health and eudemonia 
3, 4
. Raised health 
care cost and alert for personal health, evolution of 
antibiotics resistance, hope for longer life, lifestyle 
changes, and self-medication revolutionized their use 
1, 5
. 
Superior knowledge and sophistication in technology, and 
strife overturned their market 
2
. Research in the area has 
heading for making them basis for healthy civilization, 
overcoming disease, improving safety linked to them, and 
so on 
1
. Research is underway to develop and assess their 
strain, and devising and finding industrial application of 
those strains with stood-out benefits. Besides, research 
afoot to get various products containing probiotics (PCP) 
with diverse role in marketplace, which can offer new 
choice to the demand and need of all types of consumers 
6, 
7
. Their market is expanding systematically, in diverse 
domains. Further, continuing innovation and rivalry have 
potency to create novel PCP 
3, 4, 8
. 
The term “probiotics” coined in 1965 by Lilly and Stillwell 
while its definition has changed through the years. It 
defined, in present times, as “live micro-organisms which 
when administered in adequate amounts confer a health 
benefit on the host” 9. Current technological progression, 
in these fields, devised to 
7, 8, 10, 11
: 
1. Assess their efficacy, single-strain or combination 
of multiple-strains, 
2. Evaluate effect of prebiotics on their efficacy,  
single-strain- or combination of multiple-strains, and or 
3. Present PCP in various domain and or form. 
Science in these fields is budding in various domains. 
Turning this science into consumable create difficulties for 
regulatory bodies and scientific community. Side-by-side 
also imposing challenges on manufacturers 
11, 12
. Besides, 
product design consists of multistage and expensive steps 
and too time-consuming 
1
.  
Developing product is of four stages. Stage-I: evolution of 
scheme, Stage-II: design and evolution of method, Stage-
III: launch and evaluation, and Stage-IV: 
commercialization. Figure 1 presents the stages of food 
products evolution. 
Many reports published facts about boom in the variety of 
PCP and discrepancies about labeled claims and 
misidentification 
12, 13
. These discrepancies considered to 
be arising because of execution of measly quality control. 
Which, thus, have deprived consumer’s reliability on the 
marketed PCP 
13, 14
. Set up and follow of method, for 
evaluating quality and worthwhile claims, based on measly 
scientific consensus, expanded awareness of researchers 
for regulating their marketing 
12-14
. These state of affairs 
led to compliance of stricter regulations, territorial and 
global. Territorial and global controls, working in 
fragments, influence their marketing also creating disarray 
11, 12, 15
. 
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Needs of territorial and global rule states that while 
proclaiming their health claim and probiotic use, 
manufacturer has to consider 
14, 15
:  
(i) Viability of probiotic cells (VoPC) within product, 
and  
(ii) Safety issues of product, even at the end of shelf life.  
As a result, manufacturers devising approaches to prolong 
VoPC within PCP and develop smart packages 
7, 16
. Smart 
packages developed to preserve their quality and safety 
and signal discrepancies 
17
. 
For eliciting worthwhile benefit, viable-probiotics cells 
(VPC) must available in enough amounts in the intestine 
(at least, 10
9
 CFU). There, they should multiply to achieve 
satisfactory gut colonization, above stated threshold level 
12, 18
.  
Environment of making up and noncompliance to storage 
needs, during freight and storage, drop-off VoPC within 
PCP 
7, 10
. After oral administration of PCP, hydrolytic-
enzymes, acidic environment of stomach and bile salts in 
gastrointestinal (GI) tract decline VoPC 
10
. 
Diverse approaches undertaken to protect VoPC during 
processing and storage, and their GI transit. Preferentially, 
adopted approach includes 
7, 16, 19, 20
:  
(i) Manipulation of fermentation and storage 
conditions of food carriers,  
(ii) Careful selection of culture organisms,  
(iii) Addition of different growth promoters, 
protectant and prebiotics in formula, 
(iv) MEC, so on.  
Above approaches have divergent degree of successes. 
Some approaches unable to fit in high numbers of VPC 
within PCP. While other fails in conserving VoPC within 
PCP, throughout its shelf life and GI-transit phase 
7, 10
.  
Current scientific proof reveals that, VoPC within intestine 
could be sustaining by their MEC and improving their 
growth rate to lifted level referring peristalsis rate 
7
.  
Nowadays, MEC receiving interests to conserve VoPC 
within shelf life and during GI-transit phase of PCP, from 
scientific community 
7
. 
MEC of VPC potentiates in vivo action of PCP, whereas 
adding prebiotics, protectant, or both in formula further 
extend it. Later apply of gastro-resistant enteric coating 
(GREC), on microcapsules (MCs), give gastro-protection 
to encapsulated VPC side by side potentiate in vivo effect 
21-25
. MEC synergizes efficiency and effectiveness of 
PCMP 
7, 10
. Stated synergistic effects postulated to be 
attributable to follow facts associated with MEC: 
1. MEC protects VoPC from damaging environments 
(causes such as, hydrolytic-enzymes, bile salts, acidic 
environments of stomach, storage condition, and  so on), 
2. It sustains and modifies cell release, and improves 
patient compliance, and  
3. Besides, it extends shelf life and improves stability of 
PCP. 
On the contrary, MEC affects organoleptic properties of 
product. In majority cases, process of encapsulation (PEN) 
deprives aesthetic features of PCMP while improve same, 
rarely. Delivered aesthetic features depend on aesthetic 
characters of encapsulating material 
8, 26
. 
The PEN is complicate, challenging, and costly affair. The 
quality and quantity of VPC, and wished quality and 
stability of PCMP makes the method complicate and 
challenging. However, all these facts decide efficacy and 
efficiency of MEC method. 
In setting of above, this review focuses updated 
information on background, issues, and technology and 
method adopted for evolution of PCMP. Method for their 
evaluation and improving their performances and 
marketing potential also discussed. The author believes 
informative content of this paper will be useful for the 
scientific community of academic and industrial field. 
Besides, an outstanding knowledge and application of 
proper MEC technologies ought to be enough to help 
developer to get PCMP, with excellent performance. 
MICROENCAPSULATION OF PROBIOTICS 
Encapsulation, a physicochemical or mechanical process, 
enables entrapment of a substance in a material, in order, 
to make particles have diameter ranging from nanometers 
to millimeters. Encapsulation yielding particles with few 
micrometer sizes called as “MEC” 7. PEN involves 
sequential multiple steps. This starts from scattering of 
core material in a carrier matrix forming material (CMFM) 
and ends with cascading the core material with CMFM.  
PEN involves sequential steps as follows 
7
:  
1. Preparing a solution, dispersion, or agglomerate, by 
adding core material to CMFM(s) solution;  
2. Stabilizing resulting system;  
3. Developing an encapsulate, through chemical 
(polymerization) or physical (evaporation, 
solidification, coalescence) or physicochemical 
(gelification) process; and 
4. Hardening of encapsulate. 
Studies reveal that encapsulation, polymeric, shield VPC 
from harmful environments of the GI tract, and improve 
their intestinal persistency and multiplication. Further, 
PCMP posses improved patient compliance, extended shelf 
life, and sustained and modified release profile, thus may 
be an innovative or have a new role 
27
. Later application of 
GREC, as monolayer or layer-by-layer of nanolayers on 
prepared MCs of PCs conserves VoPC, on oral 
administration. This also improves its amenability for high 
water contented PCMP and shelf life 
28, 29
. 
The quality and quantity of PRs strain and their upkeep of 
viability influence choice of PEN. Further, PEN decides 
characteristics of MCs by particle shape, size, and size 
range. Coating method, PEN, and GREC influence 
efficiency of VoPC upholding during processing, storage, 
and GI-transit phase of PCMP 
7
. Co-encapsulating VPC 
with prebiotics and adding protectant in encapsulating wall 
material improve stability and performances of PCMP 
7, 11, 
16, 19
. 
OBJECTIVE AND GOAL 
The preset objective and goal of PEN linked with PCMP 
are under 
7
. 
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1. To protect VoPC in harsh environment of stomach 
and destructive storage conditions;  
2. Sustaining and releasing VPC, in plenty amounts 
(more than, 10
9
 CFU) and in metabolically active 
state, during the intestinal phase, for achieving 
enough gut colonization and conferring health benefit 
to the host;  
3. To pass on binding, complexing, or adherence ability 
to released VPC with target site, molecule, or micro-
organism or to absorb target molecule or micro-
organism in intestine; 
4. Getting MCs, water-insoluble, that will preserve its 
integrity within PCMP; 
5. Getting MCs with diverse properties having ability to 
got incorporate in a wide range of products such as 
tablets, capsules, ice-cream, yogurts, chocolates, and 
so on; and 
6. To have MCs holding satisfactory stability within 
PCMP, this could be improving shelf life. 
GREC MATERIALS AND CMFMS 
Wide range of materials used, as GREC materials and 
CMFMs, but the use of biodegradable polymer will be 
worthwhile 
30
. CMFM used are alginate, alginate-chitosan, 
gellan gum, xanthan gum, vegetable gums, carrageenan, 
sugars, starch, modified starch, dextrins, cellulose 
derivatives, hypromellose, caseinates, gelatin, glyceride 
derivatives, waxes, fats, milk proteins, zein and other 
proteins, and so on. While, commonly used GREC 
material are palm oil, poly-L-lysine, carboxymethyl 
cellulose, chitosan, hypromellose phthalate, cellulose 
acetate phthalate, and so on 
30, 31
. Among them, food 
proteins and polysaccharides considered being the 
biodegradable polymer. 
Exopolysaccharides; such as xanthan- or gellan- or 
pullulan-gum, and jamilan; could extend or modify release 
profile. Blend of xanthan or jamilan gum and gellan gum, 
alginate and xanthan or gellan gum can mend gastro-
protective feature. Further, these could be achieving colon 
targeting 
24, 25, 30
. Calcium alginate preferred as CMFM as 
is biocompatible, non-toxic, and cheaper. Besides, it 
involves simple processing steps 
30
. Hydrogel of alginate 
yields porous MCs of PRs but unable to conserve VoPC 
during GI transit phase. This needs 60-80 °C to prepare 
watery solution of alginate and creates scale-up problems. 
These problems can overcome by cascading prepared MCs 
with GREC material 
7
. While, blending alginate with 
starch or chitosan and its structural modification can 
overcome same 
32
. Starch and resistant starches can 
deliver, efficiently, VPC in the large intestine. Their 
prebiotics role ought to holds synergistic action. Surface 
feature of resistant starch could result adhesion of 
probiotics cells (PCs), to its surface. This features of 
resistant ensuring betterment of VoPC and intestinal 
targeting 
33
. Gelatin alone or in blend with gellan gum or 
other material, although, used as CMFM but unable to 
offer gastro-protection 
30
. Whey proteins and milk 
proteins, biocompatible polymers, improve aesthetic 
feature and hold excellent gelation character 
34-36
. 
Hypromellose can control release profile of PCs, extend 
their gastric retention time, and improve their gut 
colonization 
18
. Gelification feature of carrageenan could 
result entrapment of PCs. Needs for blending of dispersion 
of PCs with heat-sterilized suspension at 40-45 °C, is 
damaging. Which in-turn increase in-process loss of 
viability of probiotics (iPVLP). Besides, it owes approval, 
from several government agencies, as a food additive 
30
. 
However, chitosan haves inhibitory effects on LAB but 
can deliver VPC to colon 
28
. Further, cellulose acetate 
phthalate and hypromellose phthalate reckoned as safe and 
yield MCs, water insoluble one 
7, 18, 31
. 
General recognition is that biodegradable-biopolymers can 
deliver VPC at site of action. They can alter look, texture, 
stability, and flavor of PCMP but slightly affect their 
physicochemical features. Basing on wanted features of 
PCMP, biopolymer particles ought to crafted with wished 
features. Mended feature linked to rheology, optic, 
encapsulation, release profile, and physicochemical 
stability. Designing of biopolymer did by exploiting 
correct monomers, biopolymers, particle-creation method, 
polymerization method, and finishing steps. Commonly 
used food proteins and polysaccharides exploited for 
making up particulate-system. Particles developed 
following extrusion, gelation or solvent removal technique. 
Biopolymer based particulate conception method 
considered unsuited, either because of materials of 
nonfood-grade or increased costs of processing 
37
. 
METHOD AND PROCEDURE 
Technological choices existing for MEC are physical 
methods such as air-suspension coating, pan coating, 
spray-drying, vibrational nozzle, centrifugal extrusion. 
Substitute methods are chemical method such as in situ-, 
interfacial-, or matrix-polymerization, simple and complex 
coacervation, and so on. Among available methods, MEC 
of PCs done with spray drying, spray freeze-drying and 
impinging aerosol. Other methods are extrusion, fluidized-
bed coating and agglomeration, and direct compression 
encapsulation. Reserve methods are dispersion and ionic or 
enzymatic gelification, dispersion and interfacial-
polymerization, inter-polymer complex encapsulation with 
supercritical carbon dioxide. Although these have 
applicability in getting PCMP but have, several limits like 
involvement of organic solvents and high-pressure and or 
temperature, scale-up problems, and so on. It must accent 
that none of these methods results shelf-stable MCs loaded 
with large numbers of VPC having lasting viability 
throughout shelf life 
7, 38
. Succeeding sections provide 
method, leaning and limits of methods to get PCMP. 
Figure 2 shows Method of evolution of encapsulation 
process employed for PRs. 
SPRAY DRYING METHOD (SDM). In SDM, 
dispersion of VPC, in watery solution of CMFM, subjected 
to spraying through a sprayer or atomizer and concurrent 
drying of formed droplets, by application of hot air, in 
specially designed closed-container, to get MCs. SDM 
create MCs with quickness, duplicability, and with low 
production cost. Superior scale-up potentiality and nonstop 
processing make it amenable for industrial scale. It fails in 
protecting iPVLP, which linked to simultaneous 
dehydration and thermal inactivation 
10, 39
. While, iPVLP 
can be improve by adding protectants, such as, whey-
protein, and resistant and N-Tack starch, in formula 
33, 40
. 
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SPRAY FREEZE-DRYING METHOD (SFDM). SFDM 
involves processing steps parallel to freeze-drying and spray-
drying while removes limit of spray drying. In SFDM, 
suspension of freeze-dried VPC (FVPC) atomized into a 
cold vapor phase of a cryogenic liquid (such as liquid 
nitrogen), to achieve a dispersion of frozen droplets which 
afterwards freeze-dried. SFDM result in MCs with controlled 
size and larger specific surface areas. Referring SDM, this 
employs high-energy and long processing time, have high 
iPVLP, and increases production cost by 30–50 times. 
Ability to control release profile and improved storage 
survivability at 4 °C heightens benefit 
39, 41, 42
. High iPVLP 
issue of it improved by adding protectant, in formula, such 
as whey-protein, resistant starch, skimmed milk, and so on 
33, 
43
. 
IMPINGING AEROSOL METHOD (IAM). IAM 
involves impinging interactions of aerosols of alginate and 
aerosols of calcium chloride, from opposite directions within 
a chamber. As alginate solutions, atomized, droplet gels-out 
as they meet with calcium chloride aerosols and thus fall as 
MCs on bottom of the chamber. IAM involves scattering of 
FVPC, in alginate solution before atomization or aerosol 
formation 
44, 45
. It holds continuous processing capacity and 
high scale-up potentiality, lessens iPVLP, and protects VoPC 
in high acid and bile environment, but costly. 
DISPERSION AND IONIC-GELIFICATION METHOD 
(DIGM). DIGM employs alginate, carrageenan, or pectin as 
CMFM. These form hydrocolloid on interacting with ions 
43
. 
After making hydrocolloid, FVPC scattered in it. After 
stabilizing dispersion, by adding surfactant, cross-linking or 
hardening agent added, into it, to get MCs. DIGM has high 
scale-up potential with low iPVLP, but yields smaller sized 
particles with diverse shape having a wider range of size 
distribution. High cost and scale-up problems make it 
unsuitable for commercial scale 
10
. Layer-by-layer coatings 
of nanolayers self-assembly of polyelectrolytes, on MCs 
being did with this method 
29
. 
The alginate-starch method involves interactions of alginate 
and starch, a CMFM, with Ca
2+
, a gelling agent. Adding 
glycerol, in formula, augments survival of VPC during 
processing and storage. While inclusion of Hi-Maize starch, 
in formula, improve encapsulation efficiency 
33
. In gelatin or 
gelatin-maltodextrin based system, gelatin or gelatin-
maltodextrin employed as CMFM. While, genipin used as 
cross-linking agent, and alginate as GREC material. MCs 
prepared by interacting CMFM and cross-linking agent. 
Later application of GREC on them, with alginate, passes on 
gastro-protection to encapsulate. GREC did by cross-linking 
the alginate with Ca
2+
 following internal or external source 
method 
46, 47
. Further, whey-proteins, in amphoteric state, on 
reaction with negatively charged polysaccharides can end 
with MEC of VPC. This scheme involves pH adjustment of 
dispersion, of whey-protein, to isoelectric point of whey 
proteins, for making hydrocolloid. Then polysaccharide 
(such as pectin, carrageenan, or alginate) added, which cause 
encapsulation followed by separation of MCs 
48
. 
DISPERSION AND ENZYMATIC-GELIFICATION 
METHOD (DEGM). DEGM is an adapted version of 
DIGM. Contrary to DIGM, DEGM employs enzymes as 
gelling agent in place of ions. Further, this method employs 
rennet, an enzyme, for gelling of milk proteins, thus called 
“rennet gelification method." Concentrated watery solutions 
of milk protein, on gelling, result a high-density gel network, 
a favorable micro-milieu for encapsulated PCs, have thus 
improved applicability. Although, DEGM has improved 
feasibility for controlling particle size and has potential for 
augmenting aesthetic or sensory property but is unsuitable 
for large-scale productions. However, a prospering 
procedure resulting MCs that are water insoluble, have high 
entrapment efficiency and insignificant iPVLP, and achieve 
gastro-protection 
7, 34, 36
. 
EXTRUSION (PULSATION OR VIBRATIONAL JET 
NOZZLE) METHOD (EPVM). EPVM called cold gelation 
method and uses hydrocolloids. Hydrocolloid got by ionic or 
enzymatic gelation of CMFM. CMFM used are alginate, 
carrageenan, milk proteins, whey proteins, and so on. 
Dispersion of FVPC, in hydrocolloid of CMFM, passed 
through a nozzle at high-pressure, in droplet form, into 
solution of cross-linking or hardening agent to form MCs 
48
. 
Droplet prepared by pulsating or vibrating the jet nozzle. 
Besides, atomizers (in case of prilling technique) or 
electrostatic field used to get droplets. Alternatively, a 
coaxial flow system followed. Resulted MCs then coated 
with whey-protein, for improving aesthetic features; or 
alginate, for giving GREC. These coatings applied following 
simple immersion method 
10, 48
. 
Whey-protein based scheme uses whey-protein (denatured) 
as CMFM. This involves extruding blend of whey-protein 
isolate and FVPC followed by adjusting pH of dispersion 
below isoelectric point of whey-proteins. Prepared MCs, 
having loading efficiency up to 96%, afterward loaded in 
PCMP. Extrusion considered as a cheap and simple method, 
which involves gentle operation and can carried out under 
aerobic and anaerobic condition. The method is capable in 
minimizing iPVLP but need for later application of GREC. 
Needs for GREC and scale-up problem make it unalienable 
for commercial scale 
48, 49
. 
DISPERSION AND INTERFACIAL-
POLYMERIZATION OR COMPLEX 
COACERVATION METHOD (DIPCCM). Current 
scientific innovations have devised a single step, called 
complex coacervation. DIPCCM involves preparation of 
dispersion consisting of dispersed phase (watery suspension 
of FVPC) and continuous phase (solution of CMFM in 
organic solvent). On stabilizing dispersion, encapsulation 
resulted by adding a soluble biocompatible agent into 
continuous phase. This encapsulates PCs within a thin and 
strong membrane 
7, 50
. Watery coacervation and phase 
separation method expel exposure of PCs to non-aqueous 
solvent and heat. However, is unsuitable for commercial 
scale, while used to get mucoadhesive MCs in small-scale 
7, 
18, 31
. 
INTER-POLYMER COMPLEX ENCAPSULATION 
WITH SUPERCRITICAL CARBON DIOXIDE 
METHOD (ICESCF). Moolman et al. have patented a 
novel method, using supercritical CO2 fluid (SCF) as a 
medium for polymer processing, involving H-bond associate 
inter-polymer complexation, for PCs encapsulation 
51
. 
ICESCF involves dissolving each of complementary 
polymers at once in same SCF, or one by one to form 
separate complementary polymer solutions followed by 
mixing separate solutions together to interact contained 
complementary polymers, resulting inter-polymer complex 
solution in SCF. At least two complementary polymers, 
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having ability to interact in solution phase, is desirable, to 
form an inter-polymer complex. FVPC scattered in the 
complementary solutions before or after dissolving the 
associated polymer before interaction or mixing step. 
Otherwise, FVPC scattered in inter-polymer complex 
solution before or after dissolving the inter-polymer 
complex, before precipitating inter-polymer complex. 
Precipitation could be achievable by either changing the 
pressure and or temperature of SCF or adding a non-solvent 
constituent. Otherwise, dispersion of FVPC, in inter-polymer 
complex solution, is concentrate by spray drying the same 
after its atomization. Low molecular weight alcohol and or 
poloxamer and or ethylene oxide-propylene oxide tri-block 
copolymer used as solubilizer for improving solubility of the 
complementary polymers and or of the inter-polymer 
complex in SCF 
51
. Adding glyceryl monostearate in formula 
improves viability protecting efficiency of MCs while 
polycaprolactone and ethylene oxide-propylene oxide tri-
block copolymer decreases the same 
38, 51
. The method 
encapsulates VPC with miserly iPVLP. However, hold low 
scale-up potentiality and costlier 
38, 51
. 
FLUIDIZED-BED COATING AND 
AGGLOMERATION PROCESS (FCAP). FCAP, an 
advanced method, involve spraying solution of GREC 
material onto FVPC bed, kept under fluidized state in 
fluidized-bed processor (FBP) 
7, 10
. An advancement of 
technological substantiation, done by Lallemand group of 
Canada, recorded as patent. That involves GREC of freeze-
dried LAB with fatty acids 
52
. This invention protects 
encapsulated PCs from harsh effects of temperature, gastric 
pH, and compression 
52
. Cell Biotech has patented a dual 
coating technology for LAB (Patent number: EU 1514533). 
This involves coating of LAB with soy peptides followed by 
cellulose and gum. The method prevents the loss of VoPC 
during processing, storage, and GI transit. Further, FCAP 
hold high reproducibility and adapted to give multilayer 
coatings. It is suitable for giving GREC to prepared MCs 
within same equipment. The method owes high scale-up 
potential and is amenable for commercial scale. Associated 
high iPVLP, higher processing cost, and improved mastering 
difficulty considered as major disadvantages 
7, 10
. 
DIRECT COMPRESSION ENCAPSULATION 
METHOD (DCEM). DCEM involves pre-compression of 
FVPC and excipient blend into pellets. Latter on the pellets 
are give GREC and finally compressed as tablets. GREC has 
done in FBP, with blend of sodium alginate and 
hydroxypropyl cellulose. While compression done at 
pressures up to 90 MPa. It considered cheapest method that 
designed for commercial scale production and improving 
shelf life. DCEM has lower entrapment efficiency and higher 
iPVLP. It slows down VPC release in intestinal conditions.  
While an increase in compression pressure, decrease VoPC 
above 90 MPa 
7, 53
. 
IN-PROCESS EVALUATION 
COMPLIANCE OF REGULATORY WANTS FOR USE 
OF PROBIOTICS AND ADDITIVES. Microbial strains 
with valid identity and genetic stability, filed in dossier filed 
to regulators, should used in evolution of formula or PCMP 
15, 54-56
. FVPC subjected to species and strain determination 
test, viable cell count test, cell count tests (bacteriological, 
total aerobic bacteria, Coliforms, enterobacteria and other 
gram negative bacteria, and Yeast and Molds), and ensuring 
absence of contaminants 
15, 31
. 
Indeed, laws governing food production and use of food 
additive has grown complex, which mandates their safety 
assessment 
57, 58
. CMFMs, GREC materials, solvents, and 
additives used in formula or during evolution of PCMP 
should hold consent from regulators. Besides, they must 
complying specification for food contact substances limit, 
estimated daily intake limit, and acceptable daily intakes 
limit 
57
. Coating of feed supplement loaded MCs with 
alginate, carrageenan, gellan or xanthan restrained in some 
countries thus have to exclude from formula 
30
. 
EVALUATION OF MICROCAPSULES. Performance of 
MCs, loaded with VPC, comprises most important ingredient 
of PCMP, will oversee and control its performance. Studies 
reveal that physical properties of MCs, loaded with VPC, 
influences VoPC, during storage 
40
. Thus, for evaluating and 
up keeping inter-batch and intra-batch reproducibility and 
performance of MCs, their various limits wanted to evaluate. 
Evaluation limit set for result of percent weight gain at 
GREC stage; percent yield; entrapment efficiency; particle 
size, size distribution, zeta potential; morphological 
evaluation; flow property; accelerated stability. Besides limit 
set for result of in vitro release and release kinetic; in vivo 
performance; in vivo-in vitro correlation studies, statistical 
treatment of data, and so on 
18
. MCs also subject to assay of 
VPC, acid tolerance, bile tolerance, bile and acid tolerance 
and assimilation of cholesterol test 
59
. The flow cytometry 
and immunofluorescence method may be follow to assess 
viability of immobilized or encapsulated VPC in a rapid way 
60, 61
. 
FINAL PRODUCT EVALUATION 
Developing PCMP, with success in marketplace, involves 
costly and multistage method. Besides, involve assessment 
of microbial and physical stability, safety, sensory 
acceptance, cost of health benefit, and other essential 
sensible properties 
5, 26, 57
. 
Globalization of trade, and associated regulation, on the 
other hand, compels the manufacturers, for setting up 
uniform and scientifically acceptable quality and safety 
standards. Contamination of food borne pathogenic bacteria 
considered as a major challenge for safety and security. 
Known organisms based food hazards, arising out during 
processing, handling, or distribution as well heightens the 
safety issue. Handling issues and laws about contamination 
and food safety, major challenges, have to overcome while 
marketing food PCMP 
62
. 
Issues about contamination and safety may be address 
through constitution and execution of hazard analysis critical 
control point regulations. Besides, evolutions of protocol 
have to done to identify high-risk food and processes, and 
for preventing problems and their recurrence 
62
. 
Contamination of food borne pathogenic bacteria could 
detect with high-performance impedance bacteria biosensors 
63
. According to current guidelines use of antimicrobials and 
thermal processing, efficient in inactivating the microbial 
and virus contamination, considered being ineffective in 
improving safety. Thus, alternative technologies ought 
prerequisite to overcome inactivation linked safety issue. 
Chemiresistive immunosensors applied for direct detection 
of viruses with high sensitivity and specificity 
64
. Balancing 
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inactivation and maintenance of sensory properties as well 
challenges the processes 
62
. Optical chemical sensors and 
biosensors, having applicability, in mitigating food safety 
and security problems could employ 
17
.  
Sensory analysis considered a prerequisite for customer 
espousal and a decisive step in evolution of PCMP. This acts 
as a measure for expecting product changes has an impact on 
marketplace, which links evolution of product with 
marketplace 
1, 26
. Quantitative descriptive analysis (QDA), 
discriminative tests, affective tests, free choice profile, time-
intensity analysis methods followed, with preference, for 
getting sensory performance of PCMP. Open-ended 
question, free-listening, check-all-that-apply approach, 
sorting, multivariate adaptive regression splines, survival 
analysis method, and internal preference mapping methods 
are alternative method of sensory testing 
1, 26
. Discriminative 
tests (DCT) mark existence or absence of difference between 
samples. DCT shows whether two samples are different or 
analogous one, also quantify the degree of their similarity or 
dissimilarity with reference one. DCT may be a triangular 
test, paired-comparison test, duo–trio test (for comparison of 
two samples), or difference from control test (for more than 
two samples). Affective sensory tests point out extent of 
consumer likeliness or unlikeliness for them in hedonic 
scales, structured with 5, 7, or 9. Affective sensory tests 
report either their preference ranking (for more than two 
samples) or degree of likeliness (acceptance). The QDA and 
the free choice profile find out sensory profile with 
intensities of all descriptors in them. Time-intensity analysis 
finds out the intensity of a unique descriptor with time. 
Among all sensory test method, the QDA is put-up with 
preference 
1, 26
. 
However, for convenience MCs loaded in a suitable PCMP 
such as capsules, tablets, suspensions, creams, powders, ice 
cream, juice, nutrient and chocolate bars, and so on. Basing 
on the intended effect and use, they are got evaluated 
according to existing laws and must confirm stability test. 
PCMP presented as drug, cosmetic must comply prevailing 
rules on Drugs, and Cosmetics, while that presented, as food 
must comply Food rules 
11
. Interactions of PRs and 
prebiotics could assess by analyzing the proteomic profile 
with a μ-2DE system while rapid assessment of viability can 
do with flow cytometry 
60
. 
PACKAGING 
The packaging plays an important role in preserving 
PCMP’s quality and safety, which can made amenable to 
point out quality, safety, and security, by devising active and 
or smart packages 
17
. However, finished PCMP packed, by 
tradition, in glass containers, as PCs survival in glass bottles 
ought to be superior to in plastic bags. Biopolymer coated 
papers will promising packaging systems. Further, chemical 
or biosensors based smart-packages, ought to be more 
worthwhile, which can signal the food spoilage, packaging 
failure and contamination. 
Biopolymer coating on paper packages, results active 
packages (biodegradable), will be worthwhile over 
conventional synthetic paper coatings. Formula of 
biopolymer-coating material enables incorporation of 
various additives that ought to improve its packaging 
efficiency. Extensive study ought to needed to optimize 
compositions of active coating materials and evaluate 
packaging efficiency of biopolymer coating materials. 
Extended and further research wanted for picking up 
information on their interactions with PCs and additives and 
effect on organoleptic features. Biopolymer paper-coating 
materials, under concern are caseinates, whey protein isolate, 
isolated soy protein, wheat gluten, zein, chitosan, 
carrageenan, alginate, starch, and so on 
65
. 
Chemical or biosensors based packing will help in solving 
safety issue but increase cost of the product, distinctly, while 
their efficiency yet to found out 
17, 63, 64, 66
. Packaging system, 
under consideration, ought to be use after carrying exposure 
assessments of leach food contact substances, complying 
specifications and limit 
57
. 
FUTURE RESEARCH TRENDS IN PROBIOTICS AND 
PROBIOTICS DELIVERY 
Scientific study afoot to evaluate blend of PRs strain 
inhibiting and or displacing pathogens for specific 
microbiota aberrancies coupled to disease risk. Their 
usefulness for specific target linked human health is also 
under study 
67-70
. Research was continuing to develop low-
cost PRs strain and their blend to treat or prevent specific 
disease through adhesion or targeting of pathogens 
71, 72
. 
Systematic trials, upheld for proving therapeutic effect and 
mechanisms of action, of existing and or newer strains, 
species, or genus 
72-74
. 
Enduring researches aimed to identify and characterize 
existing strains of PRs, identify strain-specific results, find 
out best doses needed for projected effects, assess VoPC 
during GI transit, and so on. Research directed to prolong 
shelf life; conserve VoPC during processing, storage, and GI 
transit phase; optimize adhesion capacity; develop active-
packages; and evolving proper manufacturing, handling, and 
packaging techniques 
7, 67-70
.  
PROSPECTIVE ACTION PLANS 
These days, innovation considered as business mantra or 
slogan. Daily proclaim brought in, by business pundits, that 
ability to continue innovation will be only hope for resulting 
business survival. Therefore, evolution of PCMP carried 
over to fulfill the consumer’s expectancy and wish which 
considered as challenging affairs. Their evolution bit-by-bit 
thought provoking the researchers, performing in both 
scientific and applied-field of research. Research in product 
design progressed to make best formula, through method of 
optimization. Scientific way of optimizing the method 
involves determination of optimal levels of key ingredients, 
essential to get product with suitable sensory and 
physicochemical characteristics, extended shelf life, 
chemical stability, and reasonable price. The method of 
optimization ought to be a difficult task, especially when 
several causes needed to be achievable, associated with 
many features. 
Design of PCMP, a multistage method, involves several 
rudiments including huge funds. Several rudiments play 
crucial role in supervising their marketplace success and 
survivability. Amongst them, consumer acceptance a key 
issue, who must convinced and agreed to pay for the coupled 
useful claims, such as relish and fit. Therefore, PCMP must 
have suitable sensory and nutritional appeal, and worthwhile 
properties 
1
. Global and territorial guidelines and legislation 
mandated for providing information to the consumers about 
a wholesome diet and for improving the availability and 
affordability of nutritious food according to their choice. 
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Manufacturers, ought to be responsible for supplying 
products complying prevailing guidelines 
5, 57
. Considering 
discussed fact following strategy adopted for developing 
them, following PEN. 
Single or combination multiple PRs strains ought to select 
basing on projected worthwhile effects 
14, 75
. These have to 
co-encapsulate with prebiotics basing on synbiotic effect. 
Single or combinations of multiple prebiotics, ought to 
selected, basing on synbiotic effect 
76
. After selecting single 
or combination multiple strain, and prebiotics or their 
combination, additives and PEN having backing from 
regulators to select. 
GREC material or CMFM, however, should selected 
depending on wished physicochemical and surface properties 
of MCs. Their selection method as well limited with 
incompatibility and thermo-liability issues. Thus, correct 
CMFM, GREC materials, additives and packaging materials, 
to select. It is a hard task to find a single GREC material or 
CMFM, which can enclose VPC and will result MCs which 
will excel the potential for marketability of PCMP. 
Physicochemical properties of CMFM and GREC material, 
properties of core material, concentration of CMFM solution 
influence performance of MEC, for VPC. Besides, early 
concentration of PCs in formulation slurry, and limits and 
conditions of PEN influences the same. These rudiments 
have to selected, adopted, or fixed, in a judicious way 
7
. 
CMFMs and GREC material having consent from regulators, 
compatibility with other ingredients, and release-controlling 
and synbiotic feature have to use preferably. These features 
of CMFMs and GREC material will synergize effect of MCs 
and PCMP. Coating method having regulatory consent, 
which will result effective GREC, should employed. 
Concentration of CMFM solution and solution of GREC 
material influences the size and size distribution of MCs, 
efficiency of encapsulation, and effectiveness of GREC, so 
need attention. Cell loading-efficiency of MCs improves 
with increase in early cell concentration in the dispersion. 
Simple and continuous PEN having low processing cost and 
time, low iPVLP, superior scale-up potentiality and 
regulatory support should adopt. Causes influencing PEN 
efficiency, about MCs shape-size and iPVLP wants 
checking. Among discussed PEN, FCAP considered being 
convenient one followed by EVPM. This associated with 
their ease, duplicability, lessened iPVLP, lesser processing 
cost, and regulatory consent. Alternative to these, DCEM, 
following compression at pressures below 90 MPa, can 
adopt. The use of SDM with inclusion of suitable protectant 
in formula can be a wise choice. GREC of MCs, preformed, 
preferentially, has to done with FBP. Now, instrumentation 
for PEN unable to give large quantities of uniform sized 
MCs, with dwindled iPVLP, having aptness for industrial 
applications 
7
. 
Control limits have to confirmed, in judicious and scientific 
way, to get product with ideal and wanted performance. Laid 
quality control and quality assurance limits followed strictly 
during PEN, GREC, and production. Evaluation of 
performance for finished product should carry over 
according to regulatory wants, and shelf life ought to assign 
with valid stability data in proposed packages. The storage 
conditions wanted to decided, in scientific way, a limit 
critical for preserving effectiveness of PCMP 
7
. Besides, an 
efficient and smart package has to used, which can preserve 
quality of PCMP and can signal efficacy and safety of 
packaged material 
17
. Labeling want on strain specificity and 
number of VPC at end of shelf life ought to complied, 
according to laws in force, with encouraging clinical, safety, 
and stability data 
9, 15
. 
CONCLUSION 
Modern food is ever changing, with space and time, and 
turning complex day-by-day. Professionals of this field must 
work together and with industry, regulatory authorities and 
policy makers to address issues on PRs use. Effort should 
undertake to improve availability of cost-effective healthy 
product choices for consumers. Low-cost PCMP can result 
through evolution of low-cost probiotic strain or strains, and 
synbiotics combinations coupled with prevention or 
treatment of diseases or ailment. 
Importance of PEN is moving up with time with an aim to 
present large numbers of PRs containing food products such 
as capsules, tablets, suspensions, creams, powders, ice 
cream, juice, nutrient and chocolate bars, and so on. MEC of 
VPC wants well-developed technology, precise machinery, 
and better delivery systems. Confirm efficacy and efficiency 
of PCMP through human clinical trials. Ascribe are 
necessary to design and develop equipment that can give 
precise and uniform MCs of VPC in large quantities with 
lessened iPVLP and high loading efficiency while upholding 
sensory and nutritional quality.  
Future will evidence utility of PEN in devising PCMP that 
will deliver projected benefit in a cost-effective and 
sustainable way. Step to set up to arouse consumers of all 
educational levels about correct uses of PCMP, to deliver 
projected worthwhile effects to society. 
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